MSAC to review Novartis’ Kymriah

By Megan Brodie 1 year ago | In Cell and gene therapies, Reimbursement
  • 1 year ago
Deborah Henderson is alive after receiving Kymriah.

24 February 2023 The MSAC will review Novartis’ CAR-T cell therapy KYMRIAH (tisagenlecleucel) when it…

This is subscriber-only content. Please login to continue reading.